Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Trends Mol Med. 2018 Mar 30;24(5):507–520. doi: 10.1016/j.molmed.2018.03.004

Figure 2. A conceptual model schematizing known interactions critical for Vif-dependent degradation of A3 proteins.

Figure 2

The interactions between Vif, A3G and E3 ubiquitin ligase complex (1 through 6) are shown for the purpose of conceptualizing the potential number of mechanisms by which small molecules might inhibit Vif function and underscore the need to use appropriate secondary assays to validate drug-target interactions and mechanism of action in lead compound development. The model should not be taken to infer that the depicted interactions co-exist at any given time in an infected cell. PPI 1–4 (black) are interactions that current small molecules are capable of disrupting. PPI 5–6 (white) are interactions that have not yet been targeted with small molecule antagonists.